fibrinopeptide-a has been researched along with Cardiomyopathy--Hypertrophic* in 2 studies
2 other study(ies) available for fibrinopeptide-a and Cardiomyopathy--Hypertrophic
| Article | Year |
|---|---|
Relation of left atrial spontaneous echo contrast with prethrombotic state in atrial fibrillation associated with systemic hypertension, idiopathic dilated cardiomyopathy, or no identifiable cause (lone).
To investigate the association of left atrial (LA) spontaneous echo contrast with the hemostatic state in nonrheumatic atrial fibrillation (AF), we examined the plasma levels of prothrombin fragment 1+2 and fibrinopeptide A in 73 patients with chronic nonrheumatic AF undergoing transesophageal echocardiography and 38 age-matched normal subjects. The results support the theory that LA spontaneous echo contrast in nonrheumatic AF is associated with a hypercoagulable state, especially in patients with marked LA spontaneous echo contrast. Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Case-Control Studies; Echocardiography, Transesophageal; Female; Fibrinopeptide A; Heart Atria; Humans; Hypertension; Male; Middle Aged; Peptide Fragments; Protein Precursors; Prothrombin; Thromboembolism | 1998 |
The coagulation system is activated in idiopathic cardiomyopathy.
We investigated the plasma levels of molecular markers for platelet activity and the thrombotic and fibrinolytic status in patients with hypertrophic cardiomyopathy and dilated cardiomyopathy to determine the activating site of coagulation in these disorders.. A thromboembolic event is a serious complication in patients with idiopathic cardiomyopathy. However, the activating site of the coagulation system in idiopathic cardiomyopathy has not been fully investigated.. We determined the plasma levels of molecular markers for platelet activity (platelet factor 4 and beta-thromboglobulin), thrombotic status (fibrinopeptide A and thrombin-antithrombin III complex) and fibrinolytic status (D-dimer and plasmin-alpha 2-plasmin inhibitor complex) in 13 patients with hypertrophic cardiomyopathy, 17 patients with dilated cardiomyopathy and 20 normal subjects.. Plasma levels of platelet factor 4, beta-thromboglobulin and plasmin-alpha 2-plasmin inhibitor complex did not differ significantly among the three groups, whereas plasma levels of fibrinopeptide A and thrombin-antithrombin III complex in both patient groups were significantly higher than those in normal subjects. Plasma levels of D-dimer in patients with dilated cardiomyopathy were significantly higher than those in patients with hypertrophic cardiomyopathy and normal groups. In patients with hypertrophic cardiomyopathy, both fibrinopeptide A and thrombin-antithrombin III complex levels were significantly correlated with left atrial diameter. In patients with dilated cardiomyopathy, fibrinopeptide A and thrombin-antithrombin III complex levels showed a positive correlation with left ventricular end-diastolic volume and a negative correlation with fractional shortening of the left ventricle.. The activated coagulation system in patients with hypertrophic and dilated cardiomyopathy may be triggered by left atrial dilation in hypertrophic cardiomyopathy and left ventricular enlargement and dysfunction in dilated cardiomyopathy. Topics: alpha-2-Antiplasmin; Antifibrinolytic Agents; Antithrombin III; Atrial Function, Left; beta-Thromboglobulin; Blood Coagulation; Blood Coagulation Factors; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Case-Control Studies; Echocardiography; Enzyme-Linked Immunosorbent Assay; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysin; Fibrinopeptide A; Humans; Male; Middle Aged; Peptide Hydrolases; Ventricular Dysfunction, Left | 1995 |